Skip to main content

Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results

Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation; updated clinical data expected in the fourth quarter

Raised up to $185 million, including $35 million upfront, from leading investors

Successfully completed a non-human primate study for subcutaneous tegoprubart formulation

IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported its second quarter operating and financial results and reviewed recent business highlights.

“We have now transplanted nine patients in our ongoing Phase 1b kidney transplantation trial and remain highly encouraged by the results to date,” said David-Alexandre C. Gros, M.D., Chief Executive Officer. “We believe that tegoprubart could represent a significant advancement in immunosuppressive therapy following kidney transplantation and look forward to presenting updated data from our Phase 1b at a medical conference next quarter. In addition, we have started activating sites in our BESTOW Phase 2 kidney transplantation trial and are progressing towards dosing the first patient.”

Second Quarter 2023 and Recent Corporate Developments

  • Announced the closing of a financing worth up to $185 million, with $35 million in upfront funding and additional aggregate financing of up to $105 million, subject to achieving clinical development milestones, volume weighted share price levels, and trading volume conditions, as well as up to an additional $45 million upon exercise of warrants. If all commitments are met, the financing is expected to be sufficient to fund the Company through the completion of the Phase 2 BESTOW trial, subject to the achievement of specified milestones, including clinical development enrollment targets.
  • Dosed the ninth patient in the ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation. This trial will be conducted in parallel with the Phase 2 BESTOW trial. The Company anticipates reporting updated interim clinical data from the Phase 1b study in the fourth quarter of 2023.
  • Successfully completed a preclinical, non-human primate study comparing subcutaneous and intravenous tegoprubart formulations. The study results demonstrated in an animal model that tegoprubart may be safely delivered subcutaneously and that similar blood levels of drug may be achieved by both routes of administration.

Upcoming Anticipated 2023 Milestones

  • 3Q 2023: Begin enrollment in the Phase 2 BESTOW trial of tegoprubart in kidney transplantation.
  • 4Q 2023: Report updated interim clinical data from the ongoing Phase 1b trial of tegoprubart in kidney transplantation.

Second Quarter Financial Results

The company reported a net loss of $9.6 million, or $0.40 per share, for the three months ended June 30, 2023, compared to a net loss of $9.2 million, or $0.65 per share, for the same period in 2022.

Research and development expenses were $7.2 million for the three months ended June 30, 2023, compared to $5.7 million for the comparable period in 2022, an increase of $1.5 million. The increase in research and development spend primarily reflects an increase in clinical development costs, personnel costs and costs related to the production of clinical trial materials.

General and administrative expenses were $3.2 million for the three months ended June 30, 2023, compared to $3.5 million for the comparable period in 2022, a decrease of $0.3 million. The decrease was primarily related to lower professional service costs.

The company had approximately $71.4 million in cash and cash equivalents and short-term investments as of June 30, 2023, compared to $56.4 million in cash and cash equivalents as of December 31, 2022. Cash and cash equivalents and short-term investments at June 30, 2023 included net cash proceeds received from the Securities Purchase Agreement entered into on April 28, 2023.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals is a clinical stage biotechnology company with immunology expertise that is developing therapies to protect and prevent rejection of transplanted organs, as well as to treat amyotrophic lateral sclerosis (ALS). The Company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at

Follow Eledon Pharmaceuticals on social media: LinkedInTwitter

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, the company’s capital resources and ability to finance planned clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sides, as well as patient enrollment; risks relating to costs of clinical trials and the sufficiency of the company’s capital resources to fund planned clinical trials; and risks associated with the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047

Media Contact:

Jenna Urban
Berry & Company Public Relations
(212) 253 8881

Source: Eledon Pharmaceuticals

(In thousands, except share data)
  June 30,
  December 31,
Current assets:      
Cash and cash equivalents $40,947  $56,409 
Short-term investments  30,431    
Prepaid expenses and other current assets  2,244   3,109 
Total current assets  73,622   59,518 
Operating lease asset, net  553   739 
In-process research and development  32,386   32,386 
Other assets  224   150 
Total assets $106,785  $92,793 
Current liabilities:      
Accounts payable $2,197  $2,200 
Current operating lease liabilities  390   363 
Accrued expenses and other liabilities  2,313   3,912 
Total current liabilities  4,900   6,475 
Deferred tax liabilities  1,752   1,752 
Non-current operating lease liabilities  184   383 
Total liabilities  6,836   8,610 
Commitments and contingencies      
Stockholders’ equity:      
Preferred stock, $0.001 par value, 5,000,000 shares authorized at June 30,     
2023 and December 31, 2022:
Series X1 non-voting convertible preferred stock, $0.001 par value,
515,000 shares designated; 110,086 and 117,970 shares issued and
outstanding at June 30, 2023 and December 31, 2022, respectively
Series X non-voting convertible preferred stock, $0.001 par value,
10,000 shares designated; 4,422 and 6,204 shares issued and
outstanding at June 30, 2023 and December 31, 2022, respectively
Common stock, $0.001 par value, 200,000,000 shares authorized at June 30,     
2023 and December 31, 2022; 23,043,933 and 13,776,788 shares issued and
outstanding at June 30, 2023 and December 31, 2022, respectively
  23   14 
Additional paid-in capital  323,142   287,034 
Accumulated deficit  (223,216)  (202,865)
Total stockholders’ equity  99,949   84,183 
Total liabilities and stockholders’ equity $106,785  $92,793 

(In thousands, except share and per share data)
  For the Three Months
Ended June 30,
  For the Six Months
Ended June 30,
  2023  2022  2023  2022 
Operating expenses            
Research and development $7,201  $5,743  $15,314  $12,378 
General and administrative  3,153   3,540   6,150   6,764 
Total operating expenses  10,354   9,283   21,464   19,142 
Loss from operations  (10,354)  (9,283)  (21,464)  (19,142)
Other income, net  775   36   1,113   31 
Net loss and comprehensive loss $(9,579) $(9,247) $(20,351) $(19,111)
Net loss per share, basic and diluted $(0.40) $(0.65) $(1.06) $(1.34)
Weighted-average common shares outstanding, basic and diluted  24,006,549   14,265,905   19,173,080   14,299,969 

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.